In the early 90s American authors estimated that if a theoretical new drug was introduced that was capable of changing the natural course of the disease and reducing direct non-drug medical costs (including hospitalisation and surgery) by 20%, despite doubling the overall drugs bill, there would still be a reduction in total direct medical costs of Crohn's disease by 13%. Infliximab proved to be efficacious in reducing and maintaining remission in moderate to severe active Crohn's disease and/or fistulising Crohn's disease. A higher acquisition cost still remains its major limitation. Currently only the use of infliximab in case of treatment for flares seems to be cost-effective. However, this statement may be modified in the near future.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4697038 | PMC |
| http://dx.doi.org/10.5114/pg.2015.55749 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Methotrexate and Anti-TNF Combination Therapy in Adults with Refractory Crohn's Disease.
Middle East J Dig Dis
October 2024
Digestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Background: Biological medications have played a significant role in maintenance therapy for Crohn's disease (CD), but some cases become refractory to these agents. Methotrexate (MTX) appears to be a cost-effective and readily available drug for enhancing the effectiveness of maintenance therapy when used in combination with anti-tumor necrosis factor (anti-TNF) therapy in such cases. However, its effectiveness is still to be established.
View Article and Find Full Text PDFFactors affecting perception and acceptance of colonoscopy in patients with inflammatory bowel disease.
Prev Med Rep
January 2025
Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Objective: The noncompliance rate with routine or surveillance colonoscopies is high, and the underlying reasons remain unverified among Asian patients with inflammatory bowel disease (IBD). This study aimed to examine the perceptions of Asian patients with IBD regarding bowel preparation and colonoscopy and their attitudes toward the recommended intervals for colonoscopies.
Methods: Using data from one medical center between July 2020 and May 2022, we analyzed the perceptions of bowel preparation and colonoscopy and attitudes toward examination intervals among 94 patients with IBD (Crohn's disease, 41; ulcerative colitis, 53).
hsa_circ_0015388 Reduces Macrophage Derived Reactive Oxygen Species in Crohn's Disease.
Inflamm Bowel Dis
January 2025
Division of Metabolism and Biosystemic Science, Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa Hokkaido, 078-8510, Japan.
Background: Crohn's disease (CD) is a refractory inflammatory bowel disease with an unclear etiology. CircularRNA (circRNA) has been highlighted as a novel class of functional noncoding RNAs associated with the pathogenesis of various diseases. However, the functions of circRNA in CD remain unclear.
View Article and Find Full Text PDFPhysical activity pattern and its influencing factors among patients with inflammatory bowel disease in East China.
BMJ Open
December 2024
Department of Gastroenterology, Ningbo Medical Centre Lihuili Hospital, Ningbo, Zhejiang, China.
Objective: To investigate the current level of physical activity (PA) and its influencing factors among patients with inflammatory bowel disease (IBD) in East China.
Design: Cross-sectional study.
Setting: Questionnaire survey recruiting from six tertiary referral hospitals in East China between October and December 2023.
Gut bacteria Prevotellaceae related lithocholic acid metabolism promotes colonic inflammation.
J Transl Med
January 2025
Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China.
Background: The conversion of primary bile acids to secondary bile acids by the gut microbiota has been implicated in colonic inflammation. This study investigated the role of gut microbiota related bile acid metabolism in colonic inflammation in both patients with inflammatory bowel disease (IBD) and a murine model of dextran sulfate sodium (DSS)-induced colitis.
Methods: Bile acids in fecal samples from patients with IBD and DSS-induced colitis mice, with and without antibiotic treatment, were analyzed using ultraperformance liquid chromatography-mass spectrometry (UPLC-MS).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!